Skip to main content

Advertisement

SpringerLink
Log in

Is Prevention a Realistic Goal for Schizophrenia?

  • Schizophrenia and Other Psychotic Disorders (S Siegel, Section Editor)
  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Over the past 2 decades, increased efforts have focused on identifying those at genetic or clinical risk for psychosis and promoting interventions that may alter the onset or trajectory of schizophrenia. We review studies published between 2010–2013 that: (1) investigate at-risk states for psychosis in larger epidemiological studies; (2) identify causes of certain clinical presentations of the schizophrenia phenotype and (3) investigate focused and multidisciplinary approaches to treat early clinical symptoms. The article places these recent studies within the context of prior research and the concept of potential measures to prevent or ameliorate the onset of psychosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Recent papers of particular interest have been highlighted as: *Of importance **Of major importance

  1. National Institute of Mental Health NIoM. 2013; Available from: http://www.nimh.nih.gov/statistics/1schiz.shtml.

  2. Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005;66(9):1122–9.

    Article  PubMed  Google Scholar 

  3. Fusar-Poli P, Borgwardt S. Predictive power of attenuated psychosis syndrome: is it really low? The case of mild cognitive impairment. Schizophr Res. 2012;135(1–3):192–3.

    Article  PubMed  Google Scholar 

  4. Brewer WJ, Francey SM, Wood SJ, Jackson HJ, Pantelis C, Phillips LJ, et al. Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. Am J Psychiatry. 2005;162(1):71–8.

    Article  PubMed  Google Scholar 

  5. Gooding DC, Tallent KA, Matts CW. Clinical status of at-risk individuals 5 years later: further validation of the psychometric high-risk strategy. J Abnorm Psychol. 2005;114(1):170–5.

    Article  PubMed  Google Scholar 

  6. Kwapil TR. Social anhedonia as a predictor of the development of schizophrenia-spectrum disorders. J Abnorm Psychol. 1998;107(4):558–65.

    Article  PubMed  CAS  Google Scholar 

  7. Chapman LJ, Chapman JP, Kwapil TR, Eckblad M, Zinser MC. Putatively psychosis-prone subjects 10 years later. J Abnorm Psychol. 1994;103(2):171–83.

    Article  PubMed  CAS  Google Scholar 

  8. McGorry PD, Yung AR, Phillips LJ. The "close-in" or ultra high-risk model: a safe and effective strategy for research and clinical intervention in prepsychotic mental disorder. Schizophr Bull. 2003;29(4):771–90.

    Article  PubMed  Google Scholar 

  9. Phillips LJ, Yung AR, McGorry PD. Identification of young people at risk of psychosis: validation of Personal Assessment and Crisis Evaluation Clinic intake criteria. Aust N Z J Psychiatry. 2000;34 Supplement:S164-9.

    Google Scholar 

  10. McGlashan TH, Miller TJ, Woods SW, Rosen JL, Hoffman RE, Davidson L. Structured Interview for Prodromal Syndromes, Version 4.0. Prime Clinic Yale School of Medicine: New Haven, CT; 2003.

    Google Scholar 

  11. Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia L, et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry. 2012;69(3):220–9. Meta-analysis included 2,502 clinical high-risk patients from 27 studies published through January 2011. The risk of developing psychosis in ultra-high risk individuals was 18 % at 6-month follow-up, 22% at 1year, 29 % at 2years and 36% after 3 years. Risk was moderated by the age of participants, treatments, diagnostic criteria and publication year.

    Article  PubMed  Google Scholar 

  12. Tsuang MT, Van Os J, Tandon R, Barch DM, Bustillo J, Gaebel W, et al. Attenuated psychosis syndrome in DSM-5. Schizophr Res. 2013;150(1):31–5.

    Article  PubMed  Google Scholar 

  13. Linscott RJ, van Os J. An updated and conservative systematic review and meta-analysis of epidemiological evidence on psychotic experiences in children and adults: on the pathway from proneness to persistence to dimensional expression across mental disorders. Psychol Med. 2013;43(6):1133–49. Conducted a meta-analysis of incidence and prevalence of psychotic experiences in 61 cohorts. The median annual incidence of psychotic experiences was 2.5%, and the prevalence was 7.2%. Approximately 20% of those reporting psychotic experiences developed persistent symptoms, with approximately 7.4% developing a psychotic disorder.

  14. Kaymaz N, Drukker M, Lieb R, Wittchen HU, Werbeloff N, Weiser M, et al. Do subthreshold psychotic experiences predict clinical outcomes in unselected non-help-seeking population-based samples? A systematic review and meta-analysis, enriched with new results. Psychol Med. 2012;42(11):2239–53.

    Article  PubMed  CAS  Google Scholar 

  15. Wigman JT, van Winkel R, Raaijmakers QA, Ormel J, Verhulst FC, Reijneveld SA, et al. Evidence for a persistent, environment-dependent and deteriorating subtype of subclinical psychotic experiences: a 6-year longitudinal general population study. Psychol Med. 2011;41(11):2317–29.

    Article  PubMed  CAS  Google Scholar 

  16. Poulton R, Caspi A, Moffitt TE, Cannon M, Murray R, Harrington H. Children's self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. Arch Gen Psychiatry. 2000;57(11):1053–8.

    Article  PubMed  CAS  Google Scholar 

  17. Schimmelmann BG, Walger P, Schultze-Lutter F. The significance of at-risk symptoms for psychosis in children and adolescents. Can J Psychiatry. 2013;58(1):32–40.

    PubMed  Google Scholar 

  18. Calkins ME, Moore TM, Merikangas KR, Burstein M, Satterthwaite T, Bilker WB, Ruparel K, Chiavacci R, Wolf D, Mentch FD, Qiu H, Connolly J, Sleiman PM, Hakonarson H, Gur RC, Gur RE. The psychosis spectrum in a young community sample: Findings from the Philadelphia Neurodevelopmental Cohort. Under Review. A total of 7,054 children aged 11–21 and their caregivers from the Philadelphia Neurodevelopmental Cohort were screened for major domains of psychopathology and psychosis spectrum symptoms; 20.0 % of medically healthy youths reported significant psychosis spectrum symptoms.

  19. Dominguez MD, Saka MC, Lieb R, Wittchen HU, van Os J. Early expression of negative/disorganized symptoms predicting psychotic experiences and subsequent clinical psychosis: a 10-year study. Am J Psychiatry. 2010;167(9):1075–82.

    Article  PubMed  Google Scholar 

  20. Addington J, Cornblatt BA, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, et al. At clinical high risk for psychosis: outcome for nonconverters. The American journal of psychiatry. 2011;168(8):800–5.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Fusar-Poli P, Yung AR, McGorry P, van Os J. Lessons learned from the psychosis high-risk state: towards a general staging model of prodromal intervention. Psychol Med. 2013:1–8.

  22. Schultze-Lutter F, Ruhrmann S, Picker H, von Reventlow HG, Brockhaus-Dumke A, Klosterkotter J. Basic symptoms in early psychotic and depressive disorders. Br J Psychiatry Suppl. 2007;51:s31–7.

    Article  PubMed  Google Scholar 

  23. Stefanis NC, Hanssen M, Smirnis NK, Avramopoulos DA, Evdokimidis IK, Stefanis CN, et al. Evidence that three dimensions of psychosis have a distribution in the general population. Psychol Med. 2002;32(2):347–58.

    Article  PubMed  CAS  Google Scholar 

  24. De Loore E, Gunther N, Drukker M, Feron F, Sabbe B, Deboutte D, et al. Persistence and outcome of auditory hallucinations in adolescence: a longitudinal general population study of 1800 individuals. Schizophr Res. 2011;127(1–3):252–6.

    Article  PubMed  Google Scholar 

  25. Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry. 2008;65(1):28–37.

    Article  PubMed Central  PubMed  Google Scholar 

  26. Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rossler A, Schultze-Lutter F, et al. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry. 2013;70(1):107–20.

    Article  PubMed  Google Scholar 

  27. Algon S, Yi J, Calkins ME, Kohler C, Borgmann-Winter KE. Evaluation and treatment of children and adolescents with psychotic symptoms. Curr Psychiatry Rep. 2012;14(2):101–10.

    Article  PubMed Central  PubMed  Google Scholar 

  28. Pollak TA, McCormack R, Peakman M, Nicholson TR, David AS. Prevalence of anti-N-methyl-d-aspartate (NMDA) antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis. Psychol Med. 2013:1–13.

  29. Barry H, Hardiman O, Healy DG, Keogan M, Moroney J, Molnar PP, et al. Anti-NMDA receptor encephalitis: an important differential diagnosis in psychosis. Br J Psychiatry. 2011;199(6):508–9.

    Article  PubMed  Google Scholar 

  30. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091–8.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  31. Tidswell J, Kleinig T, Ash D, Thompson P, Galletly C. Early recognition of anti-N-methyl D-aspartate (NMDA) receptor encephalitis presenting as acute psychosis. Australas Psychiatry. 2013;21(6):596–9.

    Article  PubMed  Google Scholar 

  32. Benjamin S, Lauterbach MD, Stanislawski AL. Congenital and acquired disorders presenting as psychosis in children and young adults. Child Adolesc Psychiatr Clin N Am. 2013;22(4):581–608.

    Article  PubMed  Google Scholar 

  33. Armando M, Girardi P, Vicari S, Menghini D, Digilio MC, Pontillo M, et al. Adolescents at ultra-high risk for psychosis with and without 22q11 deletion syndrome: a comparison of prodromal psychotic symptoms and general functioning. Schizophr Res. 2012;139(1–3):151–6.

    Article  PubMed  Google Scholar 

  34. Tang SX, Yi JJ, Calkins ME, Whinna DA, Kohler CG, Souders MC, McDonald-McGinn DM, Zackai EH, Emanuel BS, Gur RC, Gur RE. Psychiatric disorders in 22q11.2 deletion syndrome are prevalent but undertreated. Psychol Med. 2013:1–11.

  35. Constantinides P, Vincent P. Chronic gamma-hydroxybutyric-acid use followed by gamma-hydroxybutyric-acid withdrawal mimic schizophrenia: a case report. Cases J. 2009;2:7520.

    Article  PubMed Central  PubMed  Google Scholar 

  36. Tarabar AF, Nelson LS. The gamma-hydroxybutyrate withdrawal syndrome. Toxicol Rev. 2004;23(1):45–9.

    Article  PubMed  CAS  Google Scholar 

  37. Salokangas RK, Ruhrmann S, von Reventlow HG, Heinimaa M, Svirskis T, From T, Luutonen S, Juckel G, Linszen D, Dingemans P, Birchwood M, Patterson P, Schultze-Lutter F, Klosterkotter J. Axis I diagnoses and transition to psychosis in clinical high-risk patients EPOS project: prospective follow-up of 245 clinical high-risk outpatients in four countries. Schizophr Res. 2012;138(2–3):192–7. Of 245 young patients with clinical high risk, during 18 month follow-up 37 developed psychosis. Diagnoses of bipolar disorder, unipolar depressive disorder and somatoform disorders were positively correlated with transition to psychosis, while anxiety disorders were negatively correlated.

  38. Kelleher I, Keeley H, Corcoran P, Ramsay H, Wasserman C, Carli V, Sarchiapone M, Hoven C, Wasserman D, Cannon M. Childhood trauma and psychosis in a prospective cohort study: cause, effect, and directionality. The American journal of psychiatry. 2013;170(7):734–41. A total of 1,113 school-based adolescents ages 13–16 years. Children were assessed for trauma and psychotic symptoms at baseline, 3 months and 12 months. Trauma was found to be highly predictive of hallucinations. Relationships between trauma and psychotic symptoms were also bidirectional. Cessation of trauma was correlated with decreased subseqent psychotic symptoms.

  39. Tikka M, Luutonen S, Ilonen T, Tuominen L, Kotimaki M, Hankala J, et al. Childhood trauma and premorbid adjustment among individuals at clinical high risk for psychosis and normal control subjects. Early Interv Psychiatry. 2013;7(1):51–7.

    Article  PubMed  Google Scholar 

  40. Arseneault L, Cannon M, Fisher HL, Polanczyk G, Moffitt TE, Caspi A. Childhood trauma and children's emerging psychotic symptoms: A genetically sensitive longitudinal cohort study. The American Journal of psychiatry. 2011;168(1):65–72. Interviews of 2,232 children aged 12 revealed that childhood bullying increased RR of psychotic symptoms 2–3 times.

  41. Addington J, Case N, Saleem MM, Auther AM, Cornblatt BA, Cadenhead KS. Substance use in clinical high risk for psychosis: a review of the literature. Psychiatry: Early Interv; 2013.

    Google Scholar 

  42. Kristensen K, Cadenhead KS. Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Res. 2007;151(1–2):151–4.

    Article  PubMed Central  PubMed  Google Scholar 

  43. Dragt S, Nieman DH, Schultze-Lutter F, van der Meer F, Becker H, de Haan L, Dingemans PM, Birchwood M, Patterson P, Salokangas RK, Heinimaa M, Heinz A, Juckel G, Graf von Reventlow H, French P, Stevens H, Ruhrmann S, Klosterkotter J, Linszen DH. Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis. Acta Psychiatr Scand. 2012;125(1):45–53. Two hundred forty-five help-seeking HR individuals ages 16–35 were assessed for assessed for cannabis consumption at onset of symptoms and followed for a mean duration of 465 days. Age at onset of cannabis use was correlated with earlier age of onset of HR symptoms. Onset of cannabis use preceded symptoms in most participants. No association was found between cannabis use and conversion from HR symptoms to psychosis.

  44. Dragt S, Nieman DH, Becker HE, van de Fliert R, Dingemans PM, de Haan L, et al. Age of onset of cannabis use is associated with age of onset of high-risk symptoms for psychosis. Can J Psychiatry. 2010;55(3):165–71.

    PubMed  Google Scholar 

  45. Compton MT, Kelley ME, Ramsay CE, Pringle M, Goulding SM, Esterberg ML, et al. Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients. The American journal of psychiatry. 2009;166(11):1251–7.

    Article  PubMed Central  PubMed  Google Scholar 

  46. Addington J, Epstein I, Liu L, French P, Boydell KM, Zipursky RB. A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res. 2011;125(1):54–61.

    Article  PubMed  Google Scholar 

  47. Morrison AP, French P, Stewart SL, Birchwood M, Fowler D, Gumley AI, et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. Bmj. 2012;344:e2233.

    Article  PubMed Central  PubMed  Google Scholar 

  48. Morrison AP, French P, Walford L, Lewis SW, Kilcommons A, Green J, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry. 2004;185:291–7.

    Article  PubMed  Google Scholar 

  49. Phillips LJ, Nelson B, Yuen HP, Francey SM, Simmons M, Stanford C, et al. Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: study design and baseline characteristics. The Australian and New Zealand journal of psychiatry. 2009;43(9):818–29.

    Article  PubMed  Google Scholar 

  50. van der Gaag M, Nieman DH, Rietdijk J, Dragt S, Ising HK, Klaassen RM, et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. Schizophr Bull. 2012;38(6):1180–8.

    Article  PubMed Central  PubMed  Google Scholar 

  51. Morrison AP, French P, Parker S, Roberts M, Stevens H, Bentall RP, et al. Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophr Bull. 2007;33(3):682–7.

    Article  PubMed Central  PubMed  Google Scholar 

  52. Stafford MR, Jackson H, Mayo-Wilson E, Morrison AP, Kendall T. Early interventions to prevent psychosis: systematic review and meta-analysis. Bmj. 2013;346:f185.

    Article  PubMed Central  PubMed  Google Scholar 

  53. Fisher M, Loewy R, Hardy K, Schlosser D, Vinogradov S. Cognitive interventions targeting brain plasticity in the prodromal and early phases of schizophrenia. Annu Rev Clin Psychol. 2013;9:435–63.

    Article  PubMed  Google Scholar 

  54. Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. The American journal of psychiatry. 2011;168(5):472–85.

    Article  PubMed  Google Scholar 

  55. Rauchensteiner S, Kawohl W, Ozgurdal S, Littmann E, Gudlowski Y, Witthaus H, et al. Test-performance after cognitive training in persons at risk mental state of schizophrenia and patients with schizophrenia. Psychiatry Res. 2011;185(3):334–9.

    Article  PubMed  Google Scholar 

  56. Marker KR. COGPACK 6.0. Markersoftware: Laudenberg; 2001.

    Google Scholar 

  57. Buchanan RW, Carpenter WT. Concept of schizophrenia. In: Sadock BJ, Sadock VA, editors. Kaplan & Sadock's Comprehensive Textbook of Psychiatry. Philadelphia, PA USA; London, UK: Lippincott Williams & Wilkins; 2005. p. 1329.

  58. Bechdolf A, Wagner M, Ruhrmann S, Harrigan S, Putzfeld V, Pukrop R, et al. Preventing progression to first-episode psychosis in early initial prodromal states. Br J Psychiatry. 2012;200(1):22–9.

    Article  PubMed  CAS  Google Scholar 

  59. Urben S, Pihet S, Jaugey L, Halfon O, Holzer L. Computer-assisted cognitive remediation in adolescents with psychosis or at risk for psychosis: a 6-month follow-up. Acta Neuropsychiatrica. 2012;24:328–35.

    Article  Google Scholar 

  60. Liu CC, Chien YL, Hsieh MH, Hwang TJ, Hwu HG, Liu CM. Aripiprazole for drug-naive or antipsychotic-short-exposure subjects with ultra-high risk state and first-episode psychosis: an open-label study. J Clin Psychopharmacol. 2013;33(1):18–23.

    Article  PubMed  Google Scholar 

  61. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. The American journal of psychiatry. 2006;163(5):790–9.

    Article  PubMed  Google Scholar 

  62. Walker EF, Cornblatt BA, Addington J, Cadenhead KS, Cannon TD, McGlashan TH, et al. The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: a naturalistic study of the North American Prodrome Longitudinal Sample. Schizophr Res. 2009;115(1):50–7.

    Article  PubMed Central  PubMed  Google Scholar 

  63. Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J, Miller TJ, et al. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry. 2003;54(4):453–64.

    Article  PubMed  CAS  Google Scholar 

  64. Ruhrmann S, Bechdolf A, Kuhn KU, Wagner M, Schultze-Lutter F, Janssen B, et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br J Psychiatry Suppl. 2007;51:s88–95.

    Article  PubMed  CAS  Google Scholar 

  65. Woods SW, Tully EM, Walsh BC, Hawkins KA, Callahan JL, Cohen SJ, et al. Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study. Br J Psychiatry Suppl. 2007;51:s96–101.

    Article  PubMed  Google Scholar 

  66. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry. 2002;59(10):921–8.

    Article  PubMed  Google Scholar 

  67. McGorry PD, Nelson B, Phillips LJ, Yuen HP, Francey SM, Thampi A, et al. Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome. J Clin Psychiatry. 2013;74(4):349–56.

    Article  PubMed  CAS  Google Scholar 

  68. Cornblatt BA, Lencz T, Smith CW, Olsen R, Auther AM, Nakayama E, et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry. 2007;68(4):546–57.

    Article  PubMed  CAS  Google Scholar 

  69. Fusar-Poli P, Valmaggia L, McGuire P. Can antidepressants prevent psychosis? Lancet. 2007;370(9601):1746–8.

    Article  PubMed  Google Scholar 

  70. Bowie CR, McLaughlin D, Carrion RE, Auther AM, Cornblatt BA. Cognitive changes following antidepressant or antipsychotic treatment in adolescents at clinical risk for psychosis. Schizophr Res. 2012;137(1–3):110–7.

    Article  PubMed Central  PubMed  Google Scholar 

  71. Susser E, Neugebauer R, Hoek HW, Brown AS, Lin S, Labovitz D, et al. Schizophrenia after prenatal famine. Further evidence Archives of General Psychiatry. 1996;53(1):25–31.

    Article  CAS  Google Scholar 

  72. St Clair D, Xu M, Wang P, Yu Y, Fang Y, Zhang F, et al. Rates of adult schizophrenia following prenatal exposure to the Chinese famine of 1959–1961. Jama. 2005;294(5):557–62.

    Article  PubMed  CAS  Google Scholar 

  73. McGrath J, Brown A, St CD. Prevention and schizophrenia–the role of dietary factors. Schizophr Bull. 2011;37(2):272–83.

    Article  PubMed Central  PubMed  Google Scholar 

  74. Das UN. Polyunsaturated fatty acids and their metabolites in the pathobiology of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013;42:122–34.

    Article  PubMed  CAS  Google Scholar 

  75. Kidd PM. Omega-3 DHA and EPA for cognition, behavior, and mood: clinical findings and structural-functional synergies with cell membrane phospholipids. Altern Med Rev. 2007;12(3):207–27.

    PubMed  Google Scholar 

  76. Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Archives of General Psychiatry. 2010;67(2):146–54.

    Article  PubMed  CAS  Google Scholar 

  77. Tsai GE, Lin PY. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des. 2010;16(5):522–37.

    Article  PubMed  CAS  Google Scholar 

  78. Woods SW, Walsh BC, Hawkins KA, Miller TJ, Saksa JR, D'Souza DC, et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. Eur Neuropsychopharmacol. 2013;23(8):931–40.

    Article  PubMed  CAS  Google Scholar 

  79. Nordentoft M, Thorup A, Petersen L, Ohlenschlaeger J, Melau M, Christensen TO, et al. Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment Schizophr Res. 2006;83(1):29–40.

    Google Scholar 

  80. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry. 2005;57(6):594–608.

    Article  PubMed  Google Scholar 

  81. Kavanagh DJ. Management of co-occurring substance use disorders. In: Mueser KT, Jeste DV, editors. Clinical Handbook of Schizophrenia. NY: Guilford Press; 2008. p. 459–70.

    Google Scholar 

  82. McGorry PD, Hickie IB, Yung AR, Pantelis C, Jackson HJ. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. The Australian and New Zealand Journal of Psychiatry. 2006;40(8):616–22.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

James Yi declares that he has no conflict of interest.

Karin E. Borgmann-Winter has received a grant from the National Institute of Mental Health (K23MH079498).

Monica E. Calkins has received grants from the National Institute of Mental Health (K08MH079364, MH089983, MH089924).

There are no relevant disclosures regarding Conflict of Interest for Drs. Hurford and Kohler, and for Mr. Neustadter.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Schizophrenia Center, Department of Psychiatry, University of Pennsylvania School of Medicine, 10 Gates, 3400 Spruce Street, Philadelphia, PA, 19104, USA

    Christian Kohler, Karin E. Borgmann-Winter, Irene Hurford, Eli Neustadter, James Yi & Monica E. Calkins

  2. Department of Child and Adolescent Psychiatry, Children’s Hospital of Philadelphia, Philadelphia, PA, USA

    Karin E. Borgmann-Winter & James Yi

  3. The Philadelphia Veterans Administration Hospital, Philadelphia, PA, USA

    Irene Hurford

Authors
  1. Christian Kohler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karin E. Borgmann-Winter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Irene Hurford
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eli Neustadter
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. James Yi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Monica E. Calkins
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Kohler.

Additional information

This article is part of the Topical Collection on Schizophrenia and Other Psychotic Disorders

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kohler, C., Borgmann-Winter, K.E., Hurford, I. et al. Is Prevention a Realistic Goal for Schizophrenia?. Curr Psychiatry Rep 16, 439 (2014). https://doi.org/10.1007/s11920-014-0439-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11920-014-0439-y

Keywords

Search

Navigation